Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Purdue Pharma's opioid settlement and dissolution

Purdue Pharma's opioid settlement and dissolution

Rule Changes

OxyContin maker becomes nonprofit Knoa Pharma after multi-billion dollar settlement and criminal sentence

May 1st, 2026: Purdue dissolves into Knoa Pharma

Overview

OxyContin launched in 1996 with marketing that downplayed addiction risk. Thirty years and hundreds of thousands of overdose deaths later, the company that made it no longer exists.

On May 1, 2026, Purdue Pharma was dissolved. Substantially all of its assets were transferred to Knoa Pharma, a new nonprofit owned by an independent foundation. Knoa is mandated to supply opioid use disorder treatments and overdose-reversal drugs without maximizing profit.

The dissolution implements a court-confirmed bankruptcy plan tied to a $7.4 billion settlement with state, local, and tribal governments. It follows an April 28 federal sentencing in New Jersey that imposed a $5.5 billion criminal penalty on the company.

The Sackler family, which owned and controlled Purdue for generations, is contributing the bulk of the settlement money in exchange for releases from civil claims by participating creditors. That structure was rebuilt after the Supreme Court rejected an earlier version that would have shielded the family without their consent.

Why it matters

One of the largest mass-tort cases in U.S. history is closing with a private pharmaceutical empire converted into a public-benefit drugmaker funding addiction treatment.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict

Key Indicators

$7.4B
Civil settlement
Sackler family and Purdue funds payable to states, localities, tribes, and individual victims over time.
$5.5B
Criminal penalty
Federal sentence imposed April 28, 2026 in the District of New Jersey for the company's role in the opioid epidemic.
~280,000
Prescription opioid overdose deaths
U.S. deaths involving prescription opioids since OxyContin's 1996 launch, per Centers for Disease Control and Prevention data.
6+ years
Bankruptcy duration
Time from Purdue's September 2019 Chapter 11 filing to the May 2026 dissolution.
Nonprofit
Successor structure
Knoa Pharma is owned by an independent foundation and barred from prioritizing profit over public health.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

December 1996 May 2026

13 events Latest: May 1st, 2026 · 1 month ago Showing 8 of 13
Tap a bar to jump to that date
  1. Purdue dissolves into Knoa Pharma

    Latest Corporate

    Purdue ceases operations; assets transfer to nonprofit Knoa Pharma owned by an independent foundation.

  2. New framework reached

    Negotiation

    Mediated talks produce a restructured deal with higher Sackler contributions and consent-based releases.

  3. Sackler contribution increased

    Negotiation

    Holdout states agree to revised plan after Sacklers boost contribution to roughly $6 billion.

  4. OxyContin launches

    Product

    Purdue introduces OxyContin with marketing claiming a less than 1 percent addiction rate when used for pain.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

November 1998

Tobacco Master Settlement Agreement (1998)

Forty-six state attorneys general settled with the four largest U.S. tobacco companies for an estimated $206 billion over 25 years, plus restrictions on marketing to minors. The deal followed years of state lawsuits seeking to recover Medicaid costs from smoking-related illness.

Then

States received annual payments; tobacco advertising on billboards and to youth was sharply curtailed.

Now

Funds were often diverted to general budgets rather than smoking cessation, and tobacco companies remained profitable—lessons cited by negotiators pushing for the Knoa nonprofit structure.

Why this matters now

Like the tobacco deal, the Purdue settlement converts mass-tort exposure into a multi-decade revenue stream for states, with familiar concerns about whether money reaches its intended public-health purpose.

August 1982

Johns-Manville asbestos bankruptcy (1982)

Asbestos manufacturer Johns-Manville filed Chapter 11 facing tens of thousands of injury claims. The 1988 reorganization created a trust funded by the company's stock and insurance to pay current and future claimants, and shielded the reorganized company from new asbestos suits.

Then

Trust began paying claimants at reduced cents-on-the-dollar rates as filings exceeded projections.

Now

Established the template—now codified in Section 524(g) of the Bankruptcy Code—for resolving mass torts through dedicated trusts, the structural ancestor of Purdue's settlement vehicle.

Why this matters now

Manville pioneered using bankruptcy to channel mass claims into a structured payout while keeping useful operations alive—the same logic that produced Knoa Pharma.

August 1985

A.H. Robins Dalkon Shield bankruptcy (1985)

Pharmaceutical company A.H. Robins filed Chapter 11 under thousands of injury claims from its Dalkon Shield intrauterine device. A 1988 plan funded a $2.475 billion claimants' trust and was paired with American Home Products' acquisition of the company.

Then

Trust paid roughly 200,000 claimants over more than a decade.

Now

Demonstrated that pharmaceutical mass torts could be resolved through bankruptcy with operational continuity—but also showed disputes over how much insiders should personally contribute, a question that defined the Purdue case.

Why this matters now

The Dalkon Shield case is the closest pharmaceutical analogue and shaped expectations about owner contributions in product-liability bankruptcies.

Sources

(4)